Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies
NCT ID: NCT06331117
Last Updated: 2024-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2021-04-22
2026-04-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Even though life expectancy of individuals with CS and CFCS has increased in the last years due to the improvement of patients' care and a more effective prevention of comorbidities, some of the most challenging aspects impacting on everyday living such as growth failure, accelerate senescence and skeletal-muscle defects, still need to be fully understood. This statement underlies the need to improve clinical research protocols with more innovative techniques (multi-omics profiling) in order to better understand the effect of RAS/MAPK pathway hyperactivations on different systems and to define possible personalized treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laboratory Diagnosis of of Rickettsial and Rickettsia-like Diseases
NCT01137175
Evaluation of Fanconi Syndrome and Cystinosis
NCT00004350
Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans
NCT00173355
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017
Histamine Responsiveness in McCune-Albright Syndrome
NCT00318097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group
Multiomics profiling of the RASopathies
Diagnostic test
Multiomics profiling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic test
Multiomics profiling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Leoni Chiara
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chiara Leoni, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Fondazione Policlinico A. Gemelli, IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Woman and Child Health and Public Health, Fondazione Policlinico A. Gemelli, IRCCS
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3776
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.